MedTrace Logo

Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

NCT07370207 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2026-04-13

No results posted yet for this study

Summary

This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

AHB-137

Subcutaneous injection

Sponsors & Collaborators

  • AusperBio Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Audrey Lau, MD, PhD · AusperBio Therapeutics Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-06
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Australia
  • China
  • New Zealand
  • Singapore
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07370207 on ClinicalTrials.gov